Table 1.
Information of study groups.
| Group | Drug (Dose) | Aim |
|---|---|---|
| Fatal intoxication and Control | CPZ (H a), OLA (H) | Overall metabolomics analysis; analysis of perturbed pathways; construction of a DCM. |
| Fatal intoxication and Fatal intoxication | CPZ (H), OLA (H), clozapine (H), perphenazine (H), promethazine (H), estazolam (H) |
Specificity evaluation of the panel of potential metabolites. |
| Fatal intoxication, Intoxication, Therapy, and Control | CPZ (L b and T c), OLA (L and T) | Dynamic changes of three potential metabolites at different drug levels. |
| Fatal intoxication, Intoxication, and Control | CPZ (L), OLA (L) | Sensitivity evaluation of the panel of potential metabolites. |
| Fatal intoxication, Intoxication, and Control | CPZ (H and L), OLA (H and L) | Quantitative analysis of three potential metabolites in different life states and at different doses. |
| Fatal intoxication and Control | CPZ (H), OLA (H) | Stability analysis of three potential metabolites within 10 days. |
Note: a: High dose. Only fatal intoxications were calculated. We chose several folds of LD50 for a high dose (which was the lowest lethal drug dose) to use fewer animals based on pre-experimental results. b: Low dose. Fatal intoxications and intoxications were included. We chose 2-fold LD50 for CPZ based on pre-experimental results and because the bioavailability of CPZ varies due to first-pass metabolism by the liver. c: Therapeutic dose. The treatment for this animal model was CPZ (twice a day), OLA (once a day) for 2 weeks.